Shares of Omnicell Inc. (OMCL) surged 5.13% on Monday, following the company's impressive fourth quarter 2024 earnings results that topped expectations. The healthcare technology company reported adjusted earnings per share of $0.60, surging 81.8% year-over-year and beating the consensus estimate by 5.2%.
Revenues for the quarter climbed 18.6% to $306.9 million, also exceeding analysts' projections by 3.3%. The company's gross margin expanded significantly by 547 basis points to 46.2%, driven by an improved macroeconomic environment and timing of product implementations.
For full-year 2025, Omnicell provided an upbeat outlook, forecasting revenues between $1.105 billion and $1.155 billion, with adjusted EPS in the range of $1.65 to $1.85. The company's strong performance and positive guidance fueled investor confidence, resulting in the substantial intraday stock surge.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.